Valeritas

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go Wearable Insulin Delivery Device, is designed to help patients with Type 2 diabetes in managing their insulin levels. This small, discreet, and easy-to-use device delivers continuous subcutaneous insulin infusion over 24 hours, along with on-demand bolus dosing, enabling patients to closely mimic the body’s normal physiologic pattern of insulin delivery. The company, founded in 2006, operates in the Biotechnology and Health Care sectors and is headquartered in the United States. The most recent Venture Round investment was received on 04 May 2016 from CRG and Montrose Capital Partners. Overall, Valeritas’ focus on improving the lives of diabetes patients through innovative medical technology, along with their successful commercialization of the V-Go device and significant real-world analyses confirming its efficacy, positions the company as an attractive investment opportunity in the biotechnology and healthcare industries. As of the most recent investment round in 2016, the company continues to demonstrate potential for growth and impact in the market, particularly as it holds commercial clearance in the United States and the E.U.